In business under one name or another since 1842, Laidlaw & Company is an investment banking firm with over 170 offices in the United States and Europe.
In December, 2015, the U.S. District Court of Nevada issued a legal injunction against Laidlaw & Company LTD, immediately halting all company efforts to take over Relmada Therapeutics, Inc. The injunction, which was issued with a temporary protection order against Laidlaw and its principals James Ahern and Matthew Eitner, prevents the company from continuing to provide false and misleading proxy materials in regards to their proposed takeover of Relmada Therapeutics and is the result of a lawsuit previously filed by Relmada.
Laidlaw & Company has had numerous legal problems in the past, mainly related to violating Federal financial regulations, and was at one point an investment banking service provider for Relmada. This relationship ended after a December, 2015, press release was issued by Relmada indicating that Laidlaw and it’s principals had caused negative consequences relating to the company’s NASDAQ listing and were providing false and misleading proxy information.
Matthew Eitner has served as CEO of Laidlaw & Company since 2011, and has extensive experience in the investment and equity trading industries. Mr. Eitner is also a founding member of the Board of Trustees for a Ramsey, New Jersey, Catholic preparatory high school. His associate James Ahern has been with Laidlaw & Company since 2010 as a managing partner and Head of Capital Markets. He was previously employed with Mr. Eitner at Aegis Capital Corp, and is a graduate of Northfield Mount Hermon School.